X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (35688) 35688
Book Review (6905) 6905
Publication (2612) 2612
Newsletter (358) 358
Newspaper Article (248) 248
Conference Proceeding (111) 111
Book Chapter (106) 106
Book / eBook (56) 56
Magazine Article (41) 41
Dissertation (35) 35
Trade Publication Article (14) 14
Government Document (13) 13
Web Resource (8) 8
Data Set (3) 3
Presentation (2) 2
Reference (2) 2
Report (1) 1
Streaming Video (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (33082) 33082
index medicus (32907) 32907
female (29062) 29062
oncology (17139) 17139
ovarian neoplasms - drug therapy (16168) 16168
ovarian cancer (12837) 12837
middle aged (10845) 10845
cancer (10736) 10736
adult (9381) 9381
ovarian neoplasms - pathology (9348) 9348
chemotherapy (8625) 8625
aged (8316) 8316
animals (7132) 7132
cell line, tumor (6411) 6411
ovarian-cancer (5826) 5826
antineoplastic combined chemotherapy protocols - therapeutic use (5463) 5463
obstetrics & gynecology (4733) 4733
carcinoma (4544) 4544
mice (4519) 4519
antineoplastic agents - therapeutic use (4366) 4366
prognosis (4157) 4157
male (4106) 4106
ovarian neoplasms - metabolism (4038) 4038
tumors (3966) 3966
research (3945) 3945
cisplatin (3933) 3933
care and treatment (3801) 3801
apoptosis (3747) 3747
ovarian neoplasms - genetics (3607) 3607
expression (3592) 3592
antineoplastic agents - pharmacology (3426) 3426
treatment outcome (3422) 3422
ovarian neoplasms - surgery (3278) 3278
breast-cancer (3273) 3273
neoplasm staging (3269) 3269
paclitaxel (2997) 2997
breast cancer (2993) 2993
health aspects (2964) 2964
analysis (2878) 2878
cisplatin - administration & dosage (2677) 2677
metastasis (2670) 2670
pharmacology & pharmacy (2598) 2598
drug resistance, neoplasm (2564) 2564
survival (2547) 2547
ovarian neoplasms - mortality (2421) 2421
aged, 80 and over (2379) 2379
neoplasms - drug therapy (2370) 2370
therapy (2366) 2366
apoptosis - drug effects (2334) 2334
ovarian neoplasms - therapy (2286) 2286
gene expression (2242) 2242
breast neoplasms - drug therapy (2234) 2234
proteins (2215) 2215
cancer therapies (2181) 2181
combined modality therapy (2153) 2153
paclitaxel - administration & dosage (2115) 2115
mice, nude (2105) 2105
hematology, oncology and palliative medicine (2100) 2100
tumor cells, cultured (2086) 2086
article (2049) 2049
retrospective studies (2027) 2027
genetic aspects (2023) 2023
abridged index medicus (1933) 1933
cell biology (1912) 1912
antineoplastic agents - administration & dosage (1892) 1892
disease-free survival (1892) 1892
dose-response relationship, drug (1888) 1888
antineoplastic combined chemotherapy protocols - adverse effects (1863) 1863
biochemistry & molecular biology (1859) 1859
surgery (1840) 1840
drug resistance (1839) 1839
drug therapy (1824) 1824
cell proliferation - drug effects (1815) 1815
medicine & public health (1775) 1775
carboplatin - administration & dosage (1719) 1719
cisplatin - pharmacology (1718) 1718
carboplatin (1703) 1703
risk factors (1665) 1665
medicine (1664) 1664
gene expression regulation, neoplastic (1655) 1655
survival rate (1655) 1655
cells (1641) 1641
development and progression (1616) 1616
obstetrics and gynecology (1605) 1605
ovarian carcinoma (1597) 1597
research article (1590) 1590
survival analysis (1559) 1559
immunohistochemistry (1552) 1552
xenograft model antitumor assays (1552) 1552
drug administration schedule (1532) 1532
time factors (1500) 1500
oncology, experimental (1495) 1495
adolescent (1489) 1489
antineoplastic agents - adverse effects (1484) 1484
carcinoma, ovarian epithelial (1478) 1478
mutation (1468) 1468
in-vitro (1399) 1399
cisplatin - therapeutic use (1395) 1395
medicine, research & experimental (1389) 1389
antineoplastic agents (1370) 1370
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (37) 37
Online Resources - Online (11) 11
Collection Dvlpm't (Acquisitions) - Vendor file (2) 2
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (2) 2
Collection Dvlpm't (Acquisitions) - Closed Orders (1) 1
Lakeridge Health Sciences - Online (1) 1
OISE - Stacks (1) 1
St. Michael's College (John M. Kelly) - 2nd Floor (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (33999) 33999
Japanese (574) 574
German (499) 499
French (351) 351
Chinese (272) 272
Russian (251) 251
Polish (129) 129
Italian (118) 118
Czech (58) 58
Spanish (53) 53
Hungarian (41) 41
Dutch (30) 30
Bulgarian (24) 24
Danish (18) 18
Ukrainian (17) 17
Hebrew (15) 15
Korean (15) 15
Swedish (13) 13
Croatian (11) 11
Finnish (7) 7
Portuguese (7) 7
Serbian (7) 7
Slovak (6) 6
Norwegian (5) 5
Romanian (5) 5
Turkish (5) 5
Lithuanian (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nature, ISSN 0028-0836, 2013, Volume 497, Issue 7447, pp. 108 - 112
Cancers acquire resistance to systemic treatment as a result of clonal evolution and selection(1,2). Repeat biopsies to study genomic evolution as a result of... 
HETEROGENEITY | LUNG-CANCER | ACTIVATION | EVOLUTION | VARIANTS | AXL | MULTIDISCIPLINARY SCIENCES | TAMOXIFEN RESISTANCE | TUMOR-CELLS | MUTATIONS | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Genomics | Humans | Ovarian Neoplasms - pathology | Lung Neoplasms - pathology | Antineoplastic Agents - therapeutic use | Ovarian Neoplasms - genetics | Neoplasms - genetics | DNA Mutational Analysis | Female | Antineoplastic Agents - pharmacology | DNA, Neoplasm - analysis | Ovarian Neoplasms - drug therapy | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Carcinoma, Non-Small-Cell Lung - genetics | Intercellular Signaling Peptides and Proteins - genetics | Breast Neoplasms - drug therapy | Genome, Human - genetics | Neoplasms - drug therapy | Phosphatidylinositol 3-Kinases - genetics | Drug Resistance, Neoplasm - genetics | Exome - genetics | Breast Neoplasms - genetics | Class I Phosphatidylinositol 3-Kinases | Breast Neoplasms - pathology | Retinoblastoma Protein - genetics | Plasma - chemistry | Alleles | Carcinoma, Non-Small-Cell Lung - drug therapy | DNA, Neoplasm - genetics | Neoplasms - pathology | Mediator Complex Subunit 1 - genetics | Drug Resistance, Neoplasm - drug effects | Evolution, Molecular | Antimitotic agents | Care and treatment | Physiological aspects | Dosage and administration | Genetic aspects | Research | Nucleotide sequencing | Drug resistance | Antineoplastic agents | DNA sequencing | Blood plasma | Cancer | Plasma | Biopsy | Breast cancer | Genomes | Mutation | Patients | Deoxyribonucleic acid--DNA | Tumors | Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 18, Issue 1, pp. 75 - 87
Summary Background Poly(ADP-ribose) polymerase (PARP) inhibitors have activity in ovarian carcinomas with homologous recombination deficiency. Along with BRCA1... 
Hematology, Oncology and Palliative Medicine | BRCA MUTATION | POLY(ADP-RIBOSE) POLYMERASE | RANDOMIZED PHASE-2 | ONCOLOGY | HOMOLOGOUS RECOMBINATION DEFICIENCY | MUTANT-CELLS | PROSTATE-CANCER | INHIBITORS | DNA-REPAIR | NEGATIVE BREAST-CANCER | GENOMIC LOSS | Prognosis | Prospective Studies | Follow-Up Studies | Humans | Middle Aged | Ovarian Neoplasms - pathology | Salvage Therapy | Neoplasm Recurrence, Local - drug therapy | Germ-Line Mutation - genetics | Neoplasm Recurrence, Local - pathology | Ovarian Neoplasms - genetics | Neoplasms, Glandular and Epithelial - genetics | Peritoneal Neoplasms - drug therapy | Fallopian Tube Neoplasms - genetics | Female | Antineoplastic Agents - pharmacology | Poly(ADP-ribose) Polymerases - chemistry | Ovarian Neoplasms - drug therapy | Platinum - pharmacology | Fallopian Tube Neoplasms - drug therapy | Peritoneal Neoplasms - pathology | Neoplasms, Glandular and Epithelial - pathology | Fallopian Tube Neoplasms - pathology | Survival Rate | Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use | BRCA1 Protein - genetics | International Agencies | Peritoneal Neoplasms - genetics | Neoplasms, Glandular and Epithelial - drug therapy | Carcinoma, Ovarian Epithelial | Indoles - therapeutic use | Neoplasm Recurrence, Local - genetics | Aged | Neoplasm Staging | BRCA2 Protein - genetics | Drug Resistance, Neoplasm - drug effects | Sugars | Monosaccharides | Ovarian cancer | Analysis | Carcinoma | Cancer | Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 01/2015, Volume 33, Issue 3, pp. 244 - 250
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 07/2012, Volume 30, Issue 21, pp. 2654 - 2663
Purpose The frequency of BRCA1 and BRCA2 germ-line mutations in women with ovarian cancer is unclear; reports vary from 3% to 27%. The impact of germ-line... 
POLY(ADP-RIBOSE) POLYMERASE | CLEAR-CELL | ONCOLOGY | RESISTANCE | IMPROVED SURVIVAL | HOMOLOGOUS RECOMBINATION | CARCINOMA | CARRIERS | TUMORS | CHEMOTHERAPY | FEATURES | Medical History Taking | Recurrence | Prospective Studies | Humans | Middle Aged | Ovarian Neoplasms - pathology | Drug Resistance, Neoplasm | Cystadenocarcinoma, Serous - genetics | Cystadenocarcinoma, Serous - drug therapy | Case-Control Studies | Ovarian Neoplasms - genetics | Peritoneal Neoplasms - drug therapy | Neoplasm Grading | Fallopian Tube Neoplasms - genetics | Aged, 80 and over | Genes, BRCA2 | Germ-Line Mutation | Adult | Female | Genes, BRCA1 | Ovarian Neoplasms - drug therapy | Fallopian Tube Neoplasms - drug therapy | Carcinoma - drug therapy | Carcinoma, Endometrioid - genetics | Kaplan-Meier Estimate | Mutation Rate | Treatment Outcome | Carcinoma, Endometrioid - drug therapy | Australia - epidemiology | Ovarian Neoplasms - epidemiology | Disease-Free Survival | Point Mutation | Breast Neoplasms - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Peritoneal Neoplasms - genetics | Carcinoma - genetics | Aged | Platinum Compounds - administration & dosage | Neoplasm Staging | Adenocarcinoma, Clear Cell - genetics | Adenocarcinoma, Clear Cell - drug therapy | Cohort Studies | Index Medicus | Original Reports | Gynecologic Cancer | Gync21 | Gync15
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 12/2015, Volume 33, Issue 34, pp. 4015 - 4022
Journal Article
Nature Medicine, ISSN 1078-8956, 06/2017, Volume 23, Issue 6, pp. 664 - 673
Neuroendocrine (NE) cancers are a diverse group of neoplasms typically diagnosed and treated on the basis of their site of origin. This Perspective focuses on... 
MOLECULAR CHARACTERIZATION | MEDICINE, RESEARCH & EXPERIMENTAL | PANCREATIC ENDOCRINE NEOPLASMS | TRANSGENIC MOUSE | BIOCHEMISTRY & MOLECULAR BIOLOGY | ANTIANDROGEN RESISTANCE | CONDITIONAL MOUSE MODEL | AURORA KINASE | METASTATIC PROSTATE-CANCER | T-ANTIGEN | CELL BIOLOGY | CELL LUNG-CANCER | N-MYC | Lung Neoplasms - drug therapy | Colonic Neoplasms - genetics | Carcinoma, Small Cell - genetics | Colonic Neoplasms - drug therapy | Epigenesis, Genetic | Humans | Male | Antineoplastic Agents - therapeutic use | Molecular Targeted Therapy | Tumor Suppressor Protein p53 - genetics | Ovarian Neoplasms - genetics | Neoplasms, Glandular and Epithelial - genetics | Prostatic Neoplasms - genetics | Urinary Bladder Neoplasms - genetics | Female | Cell Differentiation | Retinoblastoma Binding Proteins - genetics | Ovarian Neoplasms - drug therapy | Prostatic Neoplasms - drug therapy | Triazoles - therapeutic use | Lung Neoplasms - genetics | Antibodies, Monoclonal, Humanized - therapeutic use | Carcinoma, Neuroendocrine - drug therapy | Carcinoma, Small Cell - drug therapy | Carcinogenesis - genetics | Head and Neck Neoplasms - drug therapy | Carcinoma, Neuroendocrine - genetics | Uterine Cervical Neoplasms - drug therapy | Urinary Bladder Neoplasms - drug therapy | Uterine Cervical Neoplasms - genetics | Disease Progression | Azepines - therapeutic use | Neuroendocrine Tumors - genetics | Proto-Oncogene Proteins c-met - genetics | Cell Lineage | Cell Plasticity - genetics | Esophageal Neoplasms - genetics | Pyrimidines - therapeutic use | Neuroendocrine Tumors - drug therapy | Head and Neck Neoplasms - genetics | Proto-Oncogene Proteins c-myc - genetics | Ubiquitin-Protein Ligases - genetics | Benzodiazepines - therapeutic use | Esophageal Neoplasms - drug therapy | Proteins | Research | Health aspects | Carcinogenesis | Gastrin | Index Medicus
Journal Article
EMBO Molecular Medicine, ISSN 1757-4676, 10/2014, Volume 6, Issue 10, pp. 1279 - 1293
Epithelial‐mesenchymal transition ( EMT ) is a reversible and dynamic process hypothesized to be co‐opted by carcinoma during invasion and metastasis. Yet,... 
drug response | microarray | gene expression signature | epithelial‐mesenchymal transition | prognosis | Drug response | Epithelial-mesenchymal transition | Prognosis | Microarray | Gene expression signature | MOLECULAR SUBTYPES | MEDICINE, RESEARCH & EXPERIMENTAL | GENE-EXPRESSION SIGNATURE | STEM-CELLS | GENOMIC ANALYSES | OVARIAN-CANCER | NEGATIVE BREAST-CANCER | CLINICAL-RELEVANCE | MICRORNA CONTROL | CLAUDIN-LOW | epithelial-mesenchymal transition | SIGNATURE PREDICTS RESISTANCE | Lung Neoplasms - drug therapy | Oligonucleotide Array Sequence Analysis | Colorectal Neoplasms - genetics | Humans | Epithelial-Mesenchymal Transition - drug effects | Antineoplastic Agents - therapeutic use | Epithelial-Mesenchymal Transition - genetics | Ovarian Neoplasms - genetics | Urinary Bladder Neoplasms - genetics | Neoplasms - genetics | Colorectal Neoplasms - drug therapy | Female | Gene Expression Regulation, Neoplastic - drug effects | Ovarian Neoplasms - drug therapy | Lung Neoplasms - genetics | Stomach Neoplasms - genetics | Treatment Outcome | Transcriptome - drug effects | Transcriptome - genetics | Stomach Neoplasms - drug therapy | Urinary Bladder Neoplasms - drug therapy | Breast Neoplasms - drug therapy | Neoplasms - drug therapy | Disease-Free Survival | Breast Neoplasms - genetics | Cell Line, Tumor | Cancer patients | Chemotherapy | Patient outcomes | Stem cells | Development and progression | Drug therapy | Gene expression | Ovarian cancer | Cancer | Medical research | Breast cancer | Tumors | Mesenchyme | Colorectal carcinoma | Genomes | Metastasis | Kinases | Cancer therapies | Metastases | Breast carcinoma | Genotype & phenotype | Cell lines | Paclitaxel | Breast | Software | Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2012, Volume 366, Issue 26, pp. 2455 - 2465
Antibodies to PD-1 protein and to one of its ligands, PD-L1, have shown antitumor activity. Unleashing T cells from inhibitory signals may be a strategy to... 
MEDICINE, GENERAL & INTERNAL | LYMPHOCYTE-ASSOCIATED ANTIGEN-4 | SOLID TUMORS | RESPONSE CRITERIA | CELL ACTIVATION | IMMUNOTHERAPY | B7 FAMILY | ANTITUMOR IMMUNITY | CLINICAL ACTIVITY | PHASE-I | T-CELLS | Neoplasms - metabolism | Humans | Antibodies, Monoclonal - adverse effects | Programmed Cell Death 1 Receptor - metabolism | Antibodies, Monoclonal - therapeutic use | Male | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Stomach Neoplasms - drug therapy | Breast Neoplasms - drug therapy | Neoplasms - drug therapy | Dose-Response Relationship, Drug | Pancreatic Neoplasms - drug therapy | Antibodies, Monoclonal - administration & dosage | Antineoplastic Agents - adverse effects | Colorectal Neoplasms - drug therapy | Melanoma - drug therapy | Adult | Female | Carcinoma, Non-Small-Cell Lung - drug therapy | Programmed Cell Death 1 Receptor - immunology | Carcinoma, Renal Cell - drug therapy | Ovarian Neoplasms - drug therapy | Intravenous administration | Kidneys | Immune response | Disease | PD-1 protein | Tumor cells | Lung | Colorectal carcinoma | Body weight | Melanoma | Lymphocytes T | Breast cancer | Stomach cancer | Patients | Ovarian cancer | Pancreatic cancer | PD-L1 protein | Antitumor activity | Ligands | Autoimmune diseases | Gastric cancer | Clear cell-type renal cell carcinoma | Apoptosis | Tumors | Index Medicus | Abridged Index Medicus
Journal Article